Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zenapax-activated peptide immunotherapy.

Trial Profile

Zenapax-activated peptide immunotherapy.

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Basiliximab (Primary) ; Daclizumab; PEP-3-KLH conjugate vaccine; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ZAP IT
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 28 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top